Feb 2, 2022
First Clinical Trials to Start at Radboud Medical Centre
Award winning company MediSieve is set to start their first-in-man clinical trials in the first quarter of 2022.
The team of MediSieve has been working hard in the past month to prepare for their first clinical trials planned for the start of 2022. This is a crucial moment for the company as the company’s pivotal product will be tested in man for the first time so see if it is clinically applicable. MediSieve’s IL-6 removal product is designed to treat IL-6-driven hyperinflammation in patients with Cytokine storms, AKI, ARDS, CRS, Pancreatitis, Cardiac Surgery and others. These conditions can be present in multiple locations including ICU, Accident and Emergency, hospital wards or the home. IL-6 is an inflammatory cytokine commonly seen in hyperinflammatory diseases. IL-6 is also a major contributor to cytokine storms and is in large responsible for Covid-19 complications due to secondary sepsis. High IL-6 levels put a significant worldwide burden on the healthcare systems and have a high mortality and morbidity rate. Currently, the only treatment available is IL-6 blockers which cause immunosupression and other side effects. In vitro data suggest that MediSieve's technology can reduce adult IL-6 levels by 80% in 4 hours. The clinical trials are a seminal moment for the company to see if the results can be achieved in patients.
The trials will be held at Radboud University Medical Centre and Prof. Peter Pickkers has been appointed as the lead investigator. Peter's research focuses on pharmacological modulation on the innate immune response, and he is the head of research. Due to its extensive expertise and experience with similar clinical studies, MediSieve is fortunate and delighted to be working with Prof. Pickkers and his team.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: